Document text
Principal Investigator: Barton F. Haynes
Organization: DUKE UNIVERSITY
Fiscal Year: 2022
Award: $495,441
Funding agency: National Institute of Allergy and Infectious Diseases
The Administrative Core will coordinate the scientific and administrative activities of this IPCAVD Program,
ensuring that the Projects and Cores function well together. In particular, it will be responsible for managing
the program's financial management, program management, and coordinating Projects and Cores through
scientific meetings and communications, as well as ensuring full financial and regulatory compliance. A
primary activity of the Core will be monitoring IPCAVD progress relative to milestones and measuring this
progress against available funding to ensure resources are used efficiently. The Core will coordinate the effort
of an External Advisory Committee (EAC) that will review the progress of IPCAVD Projects and Cores, and
with input from the DAIDS Program Team, provide guidance for the Program's direction. Core staff are part of
a highly experienced and integrated management team, which will enable immediate start-up and rapid
progress. This teamwork will accelerate advancement toward the Program's goals, thus maximizing the
opportunities to positively impact HIV-1 vaccine research in humans. The Specific Aims of the Administrative
Core are as follows.
Aim 1. Provide overall IPCAVD management, coordination and supervision of the Program.
Aim 2. Ensure timely financial accounting and reporting.
Aim 3. Ensure compliance with all institutional, state, and federal research and CGMP guidelines.
Aim 4. Develop and implement IPCAVD communication, publication, and data sharing plans.
Aim 5. Provide statistical support for all data analyses.
Terms: <AIDS Virus><ALVAC><ALVAC Canarypox Vector><Accounting><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Advisory Committees><Agreement><Animal Model><Animal Models and Related Studies><Antigens><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Budgets><Cell Lineage><Clinical Trials><Communication><Contracting Opportunities><Contracts><Data><Data Analyses><Data Analysis><Data Provenance><Development><Early-Stage Clinical Trials><Ensure><Expenditure><Experimental Designs><Financial Management><Food and Drug Administration><Funding><Goals><Grant><Guidelines><HIV><HIV-1><HIV-1 vaccine><HIV-I><HIV1><HIV1 vaccine><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><IACUC><Immune response><Immunological response><Infrastructure><Institutional Animal Care and Use Committee><Institutional Policy><Investigators><LAV-HTLV-III><Lead><Lymphadenopathy-Associated Virus><Materials Testing><Measures><Messenger RNA><Modern Man><Monitor><NIH><National Institutes of Health><Occupational activity of managing finances><Outcome><Participant><Pb element><Personnel Staffing><Phase 1 Clinical Trials><Phase I Clinical Trials><Policies><Practice Guidelines><Preparation><Production><Protocol><Protocols documentation><Publications><Regulation><Reporting><Research><Research Personnel><Research Resources><Researchers><Resources><Rights><Risk><Scientific Publication><Supervision><Task Forces><Testing><Time><USFDA><United States Food and Drug Administration><United States National Institutes of Health><Universities><Vaccine Research><Virus-HIV><advisory team><conflict resolution><data interpretation><data management><data sharing><developmental><expectation><experience><heavy metal Pb><heavy metal lead><host response><immune system response><immunogen><immunoresponse><interest><mRNA><meetings><member><model of animal><model organism><phase I protocol><programs><quality assurance><vaccine platform>